CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Xolair® (Omalizumab)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00130234
NCT00130234Phase 2Completed
CompareCT.gov

Effect of Anti-IgE in Chronic Urticaria

Johns Hopkins University·interventional·Posted Aug 15, 2005·Updated May 7, 2008

In Brief

A Phase 2 clinical trial evaluating Xolair® (Omalizumab) for Urticaria. Completed, across 1 site.

Detailed Summary

This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrticaria
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2005
Enrollment StartNov 1, 2004
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.9 years ago

Interventions

Xolair® (Omalizumab)drug